Palvella Therapeutics Inc. Common Stock (PVLA)
Stock · NASDAQ · Health Care
$120.68as of 10/16/2026
Price chart
Active signals
PVLA Signal Track Record
How signals performed across all stocks →What PVLA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 30 | +5.9% | 60% | September 18, 2026 |
| Bollinger Band Breakdown | 22 | -4.7% | 36% | September 24, 2026 |
| Bollinger Band Breakout | 20 | +7.8% | 60% | September 22, 2026 |
| 200-Day Moving Average TouchActive now | 3 | +12.5% | 67% | February 4, 2025 |
| Any 20-session window (baseline) | -0.8% | 48% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PVLA
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 29
- Website
- palvellatx.com/
Fundamentals
- 1-day range
- $118.23$127.27
- Market cap
- $2.23B
- P/E (trailing)
- —
- P/E (forward)
- -15.05
- EPS (trailing)
- $-4.82
- Dividend yield
- —
- Beta
- -0.19
- Avg. volume
- 212.9K
Forecasts
15 analyst ratings
Palvella Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- PVLAPalvella Therapeutics Inc. Common Stock$120.3▼ 5.53%Market cap $2.23BP/E —$68.96$161.38
- MLYSMineralys Therapeutics Inc. Common Stock$20.3▼ 6.19%Market cap $2.23BP/E —$21.46$47.65
- SIONSionna Therapeutics Inc. Common Stock$3.89▼ 4.66%Market cap $2.24BP/E —$3.93$54.97
- URGNUroGen Pharma Ltd. Ordinary Shares$34.56▼ 5.60%Market cap $2.22BP/E —$16.37$50.81
- RAPPRapport Therapeutics Inc. Common Stock$27.57▼ 6.76%Market cap $2.22BP/E —$23.75$52.93
- BHCBausch Health Companies Inc. Common Stock$6.3▼ 0.16%Market cap $2.21BP/E —$6.1$11.08
- HRMYHarmony Biosciences Holdings Inc. Common Stock$37.95▼ 0.84%Market cap $2.26BP/E 12.36$25.52$43.49
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PVLA Palvella Therapeutics Inc. Common Stock | $2.23B | — | $120.3 | ▼ 5.53% | $68.96$161.38 |
| MLYS Mineralys Therapeutics Inc. Common Stock | $2.23B | — | $20.3 | ▼ 6.19% | $21.46$47.65 |
| SION Sionna Therapeutics Inc. Common Stock | $2.24B | — | $3.89 | ▼ 4.66% | $3.93$54.97 |
| URGN UroGen Pharma Ltd. Ordinary Shares | $2.22B | — | $34.56 | ▼ 5.60% | $16.37$50.81 |
| RAPP Rapport Therapeutics Inc. Common Stock | $2.22B | — | $27.57 | ▼ 6.76% | $23.75$52.93 |
| BHC Bausch Health Companies Inc. Common Stock | $2.21B | — | $6.3 | ▼ 0.16% | $6.1$11.08 |
| HRMY Harmony Biosciences Holdings Inc. Common Stock | $2.26B | 12.36 | $37.95 | ▼ 0.84% | $25.52$43.49 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- William Blair Initiates Coverage On Palvella Therapeutics with Outperform Ratingbenzinga · 10/16/2026
- Palvella Therapeutics: FDA Handholding Makes The Regulatory Story StrongerSeekingAlpha · 9/29/2026
- U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic MalformationsYahoo · 9/28/2026
- Palvella Therapeutics Receives Third Year Of Grant Funding From FDA Office Of Orphan Products Development For Phase 3 SELVA Trial And Ongoing Open-Label Extension Study Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Microcystic Lymphatic MalformationsBenzinga · 9/28/2026
Insider Activity
Insider Actions →- Kathleen Goin · September 16, 2026 · Option Exercise2.1K @ $9.08
- Kathleen Goin · September 16, 2026 · Option Exercise2.2K @ $7.14
- Kathleen Goin · September 16, 2026 · Sale1.7K @ $153.24
- Kathleen Goin · September 16, 2026 · Sale989 @ $152.36
- Kathleen Goin · September 16, 2026 · Sale1.7K @ $151.16
- George M. Jenkins · September 15, 2026 · Sale560 @ $151.33
- George M. Jenkins · September 15, 2026 · Sale263 @ $150.4
- George M. Jenkins · September 15, 2026 · Sale954 @ $149.38
- George M. Jenkins · September 14, 2026 · Sale1.6K @ $153.1
- George M. Jenkins · September 14, 2026 · Sale6.2K @ $152.12
- George M. Jenkins · September 14, 2026 · Sale5.6K @ $151.46
- George M. Jenkins · September 11, 2026 · Sale1.3K @ $153.06
- George M. Jenkins · September 11, 2026 · Sale4.6K @ $151.72
- George M. Jenkins · September 11, 2026 · Sale6.5K @ $150.62
- KIRITSY CHRISTOPHER P · September 2, 2026 · Option Exercise313 @ $127.2
Institutional Ownership
March 31, 2026
- Total shares held
- 13.53M
- Total value held
- $1.63B
- Institutional holders
- 176
- Unknown1.15M
- Unknown980.8K
- Unknown961.0K
- Unknown882.4K
- Unknown686.9K
- Unknown640.6K
- Unknown477.3K
- Unknown459.0K
- Unknown433.0K
- Unknown402.6K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Palvella Therapeutics Shares New Data at Dermatology Conference
Palvella Therapeutics presented three posters at the Fall Clinical Dermatology 2026 conference, sharing new data on microcystic lymphatic malformations and DSAP. This update highlights ongoing research in the company's key therapeutic areas. Meanwhile, HC Wainwright lowered its price target to $246 while maintaining its stance on the stock.
Palvella Therapeutics Shares New Data at Dermatology Conference. Palvella Therapeutics presented three posters at the Fall Clinical Dermatology 2026 conference, sharing new data on microcystic lymphatic malformations and DSAP. This update highlights ongoing research in the company's key therapeutic areas. Meanwhile, HC Wainwright lowered its price target to $246 while maintaining its stance on the stock.